# Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation

> **NCT01590979** · NA · TERMINATED · sponsor: **Northwell Health** · enrollment: 54 (actual)

## Conditions studied

- Atrial Fibrillation New Onset
- Hemorrhage
- Prolonged QTc Interval
- Ventricular Tachycardia
- Medical Care; Complications, Late Effect of Complications

## Interventions

- **DRUG:** Ranolazine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01590979
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-04
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 54 (ACTUAL)
- **Why stopped:** The study was terminated due to slow rate of accrual resulting in a sample size.
- **Last updated:** 2017-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01590979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01590979, "Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01590979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*